Obesity Related Kidney Disease

Current Diabetes Reviews

Volumn 7, Issue 1, 2011, Pages 41-49

  Mathew, Anna V ^a   Okada, Shinichi ^a   Sharma, Kumar ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adiponectin; Albuminuria; Focal sclerosis; Kidney disease; Obesity

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPOCYTOKINE; ADIPONECTIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BIOLOGICAL MARKER; CAPTOPRIL; CATHEPSIN L; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FENOFIBRATE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 4; INTERLEUKIN 6; LEPTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NEBIVOLOL; NEPHRIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ALBUMINURIA; ANTIHYPERTENSIVE THERAPY; BARIATRIC SURGERY; C57BL 6 MOUSE; CHRONIC KIDNEY DISEASE; DIABETIC PATIENT; DIET THERAPY; EXERCISE; EXPERIMENTAL MODEL; FOCAL GLOMERULOSCLEROSIS; GLOMERULOMEGALY; GLOMERULONEPHRITIS; GLOMERULOPATHY; GLOMERULOSCLEROSIS; GLOMERULUS; GLOMERULUS BASEMENT MEMBRANE; HEMODIALYSIS; HUMAN; HYPERINSULINEMIA; HYPERTENSION; HYPOALBUMINEMIA; IMMUNOGLOBULIN A NEPHROPATHY; INFLAMMATION; INSULIN RESISTANCE; KIDNEY BLOOD FLOW; KIDNEY FAILURE; LIFESTYLE MODIFICATION; MAINTENANCE THERAPY; MICROALBUMINURIA; NEPHROSCLEROSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PODOCYTE; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; WEIGHT REDUCTION; ZUCKER RAT;

EID: 79952748617     PISSN: 15733998     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339911794273928     Document Type: Review

References (101)

1. Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006; 295: 1549-1555.
2. Kramer H, Luke A, Bidani A, et al. Obesity and prevalent and incident CKD: the Hypertension Detection and Follow-Up Program. Am J Kidney Dis 2005; 46: 587-594.
3. Foster MC, Hwang SJ, Larson MG, et al. Overweight, obesity, and the development of stage 3 CKD: the Framingham Heart Study. Am J Kidney Dis 2008; 52: 39-48.
4. Johnson DW, Armstrong K, Campbell SB, et al. Metabolic syn-drome in severe chronic kidney disease: Prevalence, predictors, prognostic significance and effects of risk factor modification. Nephrology (Carlton) 2007; 12: 391-398.
5. Yoon YS, Park HS, Yun KE, Kim SB. Obesity and metabolic syn-drome-related chronic kidney disease in nondiabetic, nonhyperten-sive adults. Metabolism 2009; 58(12):1737-1742
6. Nelaj E, Gjata M, Lilaj I, et al. Factors of cardiovascular risk in patients with type 2 diabetes and incipient nephropathy. Hippokratia 2008; 12: 221-224.
7. Othman M, Kawar B, El Nahas AM. Influence of obesity on progression of non-diabetic chronic kidney disease: a retrospective cohort study. Nephron Clin Pract 2009; 113: c16-c23.
8. Kato S, Nazneen A, Nakashima Y, et al. Pathological influence of obesity on renal structural changes in chronic kidney disease. Clin Exp Nephrol 2009; 13: 332-340.
9. Kramer HJ, Saranathan A, Luke A, et al. Increasing body mass index and obesity in the incident ESRD population. J Am Soc Nephrol 2006; 17: 1453-1459.
10. Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body mass index and risk for end-stage renal disease. Ann Intern Med 2006; 144: 21-28.
11. Johansen KL, Young B, Kaysen GA, Chertow GM. Association of body size with outcomes among patients beginning dialysis. Am J Clin Nutr 2004; 80: 324-332.
12. Beddhu S, Pappas LM, Ramkumar N, Samore M. Effects of body size and body composition on survival in hemodialysis patients. J Am Soc Nephrol 2003; 14: 2366-2372.
13. Kalantar-Zadeh K, Kuwae N, Wu DY, et al. Associations of body fat and its changes over time with quality of life and prospective mortality in hemodialysis patients. Am J Clin Nutr 2006; 83: 202-210.
14. Cordeiro AC, Qureshi AR, Stenvinkel P, et al. Abdominal fat deposition is associated with increased inflammation, protein-energy wasting and worse outcome in patients undergoing haemo-dialysis. Nephrol Dial Transplant 2010; 25(2): 562-568.
15. Klausen KP, Parving HH, Scharling H, Jensen JS. Microalbuminu-ria and obesity: impact on cardiovascular disease and mortality. Clin Endocrinol (Oxf) 2009; 71: 40-45.
16. Kawar B, Bello AK, El Nahas AM. High prevalence of microal-buminuria in the overweight and obese population: data from a UK population screening programme. Nephron Clin Pract 2009; 112: c205-c212.
17. Pinto-Sietsma SJ, Navis G, Janssen WM, et al. A central body fat distribution is related to renal function impairment, even in lean subjects. Am J Kidney Dis 2003; 41: 733-741.
18. Praga M, Hernandez E, Herrero JC, et al. Influence of obesity on the appearance of proteinuria and renal insufficiency after unilateral nephrectomy. Kidney Int 2000; 58: 2111-2118.
19. Praga M, Hernandez E, Morales E, et al. Clinical features and long-term outcome of obesity-associated focal segmental glomeruloscle-rosis. Nephrol Dial Transplant 2001; 16: 1790-1798.
20. Kambham N, Markowitz GS, Valeri AM, Lin J, D'Agati VD. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 2001; 59: 1498-1509.
21. Praga M, Morales E, Herrero JC, et al. Absence of hypoalbumine-mia despite massive proteinuria in focal segmental glomeruloscle-rosis secondary to hyperfiltration. Am J Kidney Dis 1999; 33: 52-58.
22. Tran HA. Obesity-related glomerulopathy. J Clin Endocrinol Me-tab 2004; 89: 6358.
23. Serra A, Romero R, Lopez D, et al. Renal injury in the extremely obese patients with normal renal function. Kidney Int 2008; 73: 947-955.
24. Goumenos DS, Kawar B, El Nahas M, et al. Early histological changes in the kidney of people with morbid obesity. Nephrol Dial Transplant 2009; 24: 3732-3738.
25. Chen HM, Li SJ, Chen HP, et al. Obesity-related glomerulopathy in China: a case series of 90 patients. Am J Kidney Dis 2008; 52: 58-65.
26. Kramer H. Obesity and chronic kidney disease. Contrib Nephrol 2006; 151: 1-18.
27. Griffin KA, Kramer H, Bidani AK. Adverse renal consequences of obesity. Am J Physiol Renal Physiol 2008; 294: F685-F696.
28. Chagnac A, Weinstein T, Korzets A, et al. Glomerular hemody-namics in severe obesity. Am J Physiol Renal Physiol 2000; 278: F817-F822.
29. Coimbra TM, Janssen U, Grone HJ, et al. Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes. Kidney Int 2000; 57: 167-182.
30. Kasiske BL, Napier J. Glomerular sclerosis in patients with massive obesity. Am J Nephrol 1985; 5: 45-50.
31. Hoffler U, Hobbie K, Wilson R, et al. Diet-induced obesity is associated with hyperleptinemia, hyperinsulinemia, hepatic steatosis, and glomerulopathy in C57Bl/6J mice. Endocrine 2009; 36: 311-325.
32. Deji N, Kume S, Araki S, et al. Structural and functional changes in the kidneys of high-fat diet-induced obese mice. Am J Physiol Renal Physiol 2009; 296: F118-F126.
33. Jiang G, Li Z, Liu F, et al. Prevention of obesity in mice by an-tisense oligonucleotide inhibitors of stearoyl-CoA desaturase-1. J Clin Invest 2005; 115: 1030-1038.
34. Weisinger RS, Begg DP, Jois M. Antagonists of the renin-angiotensin system and the prevention of obesity. Curr Opin Inves-tig Drugs 2009; 10: 1069-1077.
35. Jalovaara K, Santaniemi M, Timonen M, et al. Low serum adi-ponectin level as a predictor of impaired glucose regulation and type 2 diabetes mellitus in a middle-aged Finnish population. Metabolism 2008; 57: 1130-1134.
36. Takemura Y, Walsh K, Ouchi N. Adiponectin and cardiovascular inflammatory responses. Curr Atheroscler Rep 2007; 9: 238-243.
37. Zoccali C, Mallamaci F, Tripepi G, et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002; 13: 134-141.
38. Nanayakkara PW, Le Poole CY, Fouque D, et al. Plasma adi-ponectin concentration has an inverse and a non linear association with estimated glomerular filtration rate in patients with K/DOQI 3 - 5 chronic kidney disease. Clin Nephrol 2009; 72: 21-30.
39. Guebre-Egziabher F, Bernhard J, Funahashi T, Hadj-Aissa A, Fou-que D. Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function. Nephrol Dial Transplant 2005; 20: 129-134.
40. Kollerits B, Fliser D, Heid IM, Ritz E, Kronenberg F. Gender-specific association of adiponectin as a predictor of progression of chronic kidney disease: the Mild to Moderate Kidney Disease Study. Kidney Int 2007; 71: 1279-1286.
41. Jorsal A, Tarnow L, Frystyk J, et al. Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy. Kidney Int 2008; 74: 649-654.
42. Saraheimo M, Forsblom C, Thorn L, et al. Serum adiponectin and progression of diabetic nephropathy in patients with type 1 diabetes. Diabetes Care 2008; 31: 1165-1169.
43. Ma K, Cabrero A, Saha PK, et al. Increased beta -oxidation but no insulin resistance or glucose intolerance in mice lacking adi-ponectin. J Biol Chem 2002; 277: 34658-34661.
44. Ohashi K, Iwatani H, Kihara S, et al. Exacerbation of albuminuria and renal fibrosis in subtotal renal ablation model of adiponectin-knockout mice. Arterioscler Thromb Vasc Biol 2007; 27: 1910-1917.
45. Faul C, Asanuma K, Yanagida-Asanuma E, Kim K, Mundel P. Actin up: regulation of podocyte structure and function by components of the actin cytoskeleton. Trends Cell Biol 2007; 17: 428-437.
46. Tsuchida A, Yamauchi T, Takekawa S, et al. Peroxisome prolifera-tor-activated receptor (PPAR)alpha activation increases adi-ponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPAR-gamma, and their combination. Diabetes 2005; 54: 3358-3370.
47. Yamauchi T, Nio Y, Maki T, et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 2007; 13: 332-339.
48. Sharma K, Ramachandrarao S, Qiu G, et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 2008; 118: 1645-1656.
49. Cammisotto PG, Bendayan M. Adiponectin stimulates phosphory-lation of AMP-activated protein kinase alpha in renal glomeruli. J Mol Histol 2008; 39: 579-584.
50. Mao X, Kikani CK, Riojas RA, et al. APPL1 binds to adiponectin receptors and mediates adiponectin signalling and function. Nat Cell Biol 2006; 8: 516-523.
51. Kastarinen H, Kesaniemi YA, Ukkola O. Leptin and lipid metabolism in chronic kidney failure. Scand J Clin Lab Invest 2009; 69: 401-408.
52. Sharma K, Considine RV, Michael B, et al. Plasma leptin is partly cleared by the kidney and is elevated in hemodialysis patients. Kidney Int 1997; 51: 1980-1985.
53. Stenvinkel P, Lindholm B, Lonnqvist F, Katzarski K, Heimburger O. Increases in serum leptin levels during peritoneal dialysis are associated with inflammation and a decrease in lean body mass. J Am Soc Nephrol 2000; 11: 1303-1309.
54. Wolf G, Hamann A, Han DC, et al. Leptin stimulates proliferation and TGF-beta expression in renal glomerular endothelial cells: potential role in glomerulosclerosis [seecomments]. Kidney Int 1999; 56: 860-872.
55. Wolf G, Ziyadeh FN. Leptin and renal fibrosis. Contrib Nephrol 2006; 151: 175-83.
56. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995; 95: 2409-2415.
57. Kern PA, Saghizadeh M, Ong JM, et al. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995; 95: 2111-2119.
58. de Luis DA, Perez Castrillón JL, Dueñas A. Leptin and obesity. Minerva Med 2009; 100: 229-236.
59. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.
60. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 1994; 43: 1271-1278.
61. Koukouritaki SB, Vardaki EA, Papakonstanti EA, et al. TNF-alpha induces actin cytoskeleton reorganization in glomerular epithelial cells involving tyrosine phosphorylation of paxillin and focal adhesion kinase. Mol Med 1999; 5: 382-392.
62. Takano Y, Yamauchi K, Hayakawa K, et al. Transcriptional suppression of nephrin in podocytes by macrophages: roles of inflammatory cytokines and involvement of the PI3K/Akt pathway. FEBS Lett 2007; 581: 421-426.
63. Ikezumi Y, Suzuki T, Karasawa T, et al. Activated macrophages down-regulate podocyte nephrin and podocin expression via stress-activated protein kinases. Biochem Biophys Res Commun 2008; 376: 706-711.
64. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001; 280: E745-E751.
65. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reac-tants and interleukin-6 with metabolic syndrome X. Diabetologia 1997; 40: 1286-1292.
66. Axelsson J, Rashid Qureshi A, Suliman ME, et al. Truncal fat mass as a contributor to inflammation in end-stage renal disease. Am J Clin Nutr 2004; 80: 1222-1229.
67. Engeli S, Feldpausch M, Gorzelniak K, et al. Association between adiponectin and mediators of inflammation in obese women. Diabetes 2003; 52: 942-947.
68. Fasshauer M, Paschke R. Regulation of adipocytokines and insulin resistance. Diabetologia 2003; 46: 1594-1603.
69. Okada S, Shikata K, Matsuda M, et al. Intercellular adhesion mole-cule-1-deficient mice are resistant against renal injury after induction of diabetes. Diabetes 2003; 52: 2586-293.
70. Hatunic M, Finucane F, Burns N, Gasparro D, Nolan JJ. Vascular inflammatory markers in early-onset obese and type 2 diabetes subjects before and after three months' aerobic exercise training. Diab Vasc Dis Res 2007; 4: 231-234.
71. Cassis LA, Police SB, Yiannikouris F, Thatcher SE. Local adipose tissue renin-angiotensin system. Curr Hypertens Rep 2008; 10: 93-98.
72. Saiki A, Ohira M, Endo K, et al. Circulating angiotensin II is associated with body fat accumulation and insulin resistance in obese subjects with type 2 diabetes mellitus. Metabolism 2009; 58: 708-713.
73. Ahmed SB, Fisher ND, Stevanovic R, Hollenberg NK. Body mass index and angiotensin-dependent control of the renal circulation in healthy humans. Hypertension 2005; 46: 1316-1320.
74. Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci USA 2003; 100: 14211-14216.
75. de Paula RB, da Silva AA, Hall JE. Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltra-tion. Hypertension 2004; 43: 41-47.
76. Shibata S, Nagase M, Yoshida S, Kawachi H, Fujita T. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension 2007; 49: 355-364.
77. Chen C, Liang W, Jia J, et al. Aldosterone induces apoptosis in rat podocytes: role of PI3-K/Akt and p38MAPK signaling pathways. Nephron Exp Nephrol 2009; 113: e26-e34.
78. Shibata S, Nagase M, Yoshida S, et al. Modification of mineralo-corticoid receptor function by Rac1 GTPase: implication in prote-inuric kidney disease. Nat Med 2008; 14: 1370-1376.
79. Mykkanen L, Zaccaro DJ, Wagenknecht LE, et al. Microalbuminu-ria is associated with insulin resistance in nondiabetic subjects: the insulin resistance atherosclerosis study. Diabetes 1998; 47: 793-800.
80. Rademacher E, Mauer M, Jacobs DR Jr., et al. Albumin excretion rate in normal adolescents: relation to insulin resistance and cardiovascular risk factors and comparisons to type 1 diabetes mellitus patients. Clin J Am Soc Nephrol 2008; 3: 998-1005.
81. Catalano C, Muscelli E, Quinones Galvan A, et al. Effect of insulin on systemic and renal handling of albumin in nondiabetic and NIDDM subjects. Diabetes 1997; 46: 868-875.
82. Ijaz A, Tejada T, Catanuto P, et al. Inhibition of C-jun N-terminal kinase improves insulin sensitivity but worsens albuminuria in experimental diabetes. Kidney Int 2009; 75: 381-388.
83. Coward RJ, Welsh GI, Yang J, et al. The human glomerular podo-cyte is a novel target for insulin action. Diabetes 2005; 54: 3095-3102.
84. Jauregui A, Mintz DH, Mundel P, Fornoni A. Role of altered insulin signaling pathways in the pathogenesis of podocyte malfunction and microalbuminuria. Curr Opin Nephrol Hypertens 2009; 18: 539-545.
85. Tseng PH, Lin HP, Hu H, et al. The canonical transient receptor potential 6 channel as a putative phosphatidylinositol 3,4,5-trisphosphate-sensitive calcium entry system. Biochemistry 2004; 43: 11701-11708.
86. Faul C, Donnelly M, Merscher-Gomez S, et al. The actin cy-toskeleton of kidney podocytes is a direct target of the antiproteinu-ric effect of cyclosporine A. Nat Med 2008; 14: 931-938.
87. Ebenezer PJ, Mariappan N, Elks CM, Haque M, Francis J. Diet-induced renal changes in Zucker rats are ameliorated by the super-oxide dismutase mimetic TEMPOL. Obesity (Silver Spring) 2009; 17: 1994-2002.
88. Ebenezer PJ, Mariappan N, Elks CM, et al. Effects of pyrrolidine dithiocarbamate on high-fat diet-induced metabolic and renal alterations in rats. Life Sci 2009; 85: 357-364.
89. Tuttle KR, Sunwold D, Kramer H. Can comprehensive lifestyle change alter the course of chronic kidney disease? Semin Nephrol 2009; 29: 512-523.
90. Praga M, Hernandez E, Andres A, et al. Effects of body-weight loss and captopril treatment on proteinuria associated with obesity. Nephron 1995; 70: 35-41.
91. Morales E, Valero MA, Leon M, Hernandez E, Praga M. Beneficial effects of weight loss in overweight patients with chronic proteinu-ric nephropathies. Am J Kidney Dis 2003; 41: 319-327.
92. Chagnac A, Weinstein T, Herman M, et al. The effects of weight loss on renal function in patients with severe obesity. J Am Soc Nephrol 2003; 14: 1480-1486.
93. Bruun JM, Helge JW, Richelsen B, Stallknecht B. Diet and exercise reduce low-grade inflammation and macrophage infiltration in adipose tissue but not in skeletal muscle in severely obese subjects. Am J Physiol Endocrinol Metab 2006; 290: E961-E967.
94. Serra A, Granada ML, Romero R, et al. The effect of bariatric surgery on adipocytokines, renal parameters and other cardiovascular risk factors in severe and very severe obesity: 1-year follow-up. Clin Nutr 2006; 25: 400-408.
95. Soto FC, Higa-Sansone G, Copley JB, et al. Renal failure, glome-rulonephritis and morbid obesity: improvement after rapid weight loss following laparoscopic gastric bypass. Obes Surg 2005; 15: 137-140.
96. Navaneethan SD, Yehnert H, Moustarah F, et al. Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2009; 4: 1565-1574.
97. Palomar R, Fernandez-Fresnedo G, Dominguez-Diez A, et al. Effects of weight loss after biliopancreatic diversion on metabolism and cardiovascular profile. Obes Surg 2005; 15: 794-798.
98. Sharma AM. Is there a rationale for angiotensin blockade in the management of obesity hypertension? Hypertension 2004; 44: 12-19.
99. Nakamura T, Sugaya T, Kawagoe Y, et al. Candesartan reduces urinary fatty acid-binding protein excretion in patients with auto-somal dominant polycystic kidney disease. Am J Med Sci 2005; 330: 161-165.
100. Kincaid-Smith P, Fairley KF, Farish S, Best JD, Proietto J. Reduction of proteinuria by rosiglitazone in non-diabetic renal disease. Nephrology (Carlton) 2008; 13: 58-62.
101. Han SH, Quon MJ, Kim JA, Koh KK. Adiponectin and cardiovascular disease: response to therapeutic interventions. J Am Coll Car-diol 2007; 49: 531-538.